SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in rare diseases and cancer treatments, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company's management will engage in a fireside chat on Wednesday, November 13, 2024, at 1:00 p.m. ET in Boston, Massachusetts. A live webcast will be available on the company's investor relations website, with a replay accessible for a time after the event.
SpringWorks Therapeutics (Nasdaq: SWTX), un'azienda biotecnologica in fase commerciale che si specializza nel trattamento di malattie rare e del cancro, ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. La direzione dell'azienda parteciperà a un colloquio informale il mercoledì 13 novembre 2024, alle 13:00 ET a Boston, Massachusetts. Una trasmissione in diretta sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda, con una registrazione accessibile per un periodo di tempo dopo l'evento.
SpringWorks Therapeutics (Nasdaq: SWTX), una empresa biofarmacéutica en etapa comercial especializada en el tratamiento de enfermedades raras y cáncer, ha anunciado su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. La dirección de la empresa participará en una charla informal el miércoles 13 de noviembre de 2024, a la 1:00 p.m. ET en Boston, Massachusetts. Una transmisión en vivo estará disponible en el sitio web de relaciones con inversores de la empresa, con una repetición accesible durante un tiempo después del evento.
SpringWorks Therapeutics (Nasdaq: SWTX), 희귀 질환 및 암 치료를 전문으로 하는 상업 단계의 생명공학 회사가 Guggenheim의 첫 번째 헬스케어 혁신 회의에 참여한다고 발표했습니다. 회사의 경영진은 2024년 11월 13일 수요일, 오후 1시 (ET)에 매사추세주 보스턴에서 진행되는 화상 대화에 참여할 예정입니다. 회사의 투자자 관계 웹사이트에서 실시간 웹캐스트를 제공하며, 행사 후 일정 기간 동안 다시 보기가 가능합니다.
SpringWorks Therapeutics (Nasdaq: SWTX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares et les traitements contre le cancer, a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. La direction de l'entreprise participera à une conversation informelle le mercredi 13 novembre 2024, à 13h00 ET à Boston, Massachusetts. Une diffusion en direct sera disponible sur le site des relations avec les investisseurs de l'entreprise, avec un enregistrement accessible pendant un certain temps après l'événement.
SpringWorks Therapeutics (Nasdaq: SWTX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene Krankheiten und Krebstherapien spezialisiert hat, hat seine Teilnahme an der Ersten Gesundheitsinnovationskonferenz von Guggenheim bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, dem 13. November 2024, um 13:00 Uhr ET in Boston, Massachusetts, an einem informellen Gespräch teilnehmen. Ein Live-Stream wird auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Aufzeichnung, die für eine gewisse Zeit nach der Veranstaltung abrufbar ist.
- None.
- None.
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m. ET.
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Investors
investors@springworkstx.com
Media
media@springworkstx.com
FAQ
When is SpringWorks Therapeutics (SWTX) presenting at Guggenheim's Healthcare Innovation Conference?
How can I watch SpringWorks Therapeutics (SWTX) presentation at the Guggenheim conference?
Will there be a replay available of SpringWorks Therapeutics (SWTX) Guggenheim conference presentation?
